H1N1 News and Research

RSS

Novel influenza A (H1N1) is a new flu virus of swine origin that was first detected in Mexico and the United States in March and April, 2009. The first novel H1N1 patient in the United States was confirmed by laboratory testing at CDC on April 15, 2009. The second patient was confirmed on April 17, 2009. It was quickly determined that the virus was spreading from person-to-person. On April 22, CDC activated its Emergency Operations Center to better coordinate the public health response. On April 26, 2009, the United States Government declared a public health emergency.

It’s thought that novel influenza A (H1N1) flu spreads in the same way that regular seasonal influenza viruses spread; mainly through the coughs and sneezes of people who are sick with the virus.

Winner Medical second quarter net sales increase 27% to $33.2 million

Winner Medical Group Inc., a leading manufacturer of medical dressings, medical disposables and non-woven fabric made from 100% natural PurCotton products in China, today reported consolidated financial results for the second quarter ended March 31, 2011.

11 May 2011

Aethlon seeks FDA meeting for re-initiation of Hemopurifier IDE study

Aethlon Medical, Inc. announces that it has submitted a request to the U.S. Food and Drug Administration for a face-to-face meeting to discuss re-initiation of an Investigational Device Exemption (IDE) study of the Aethlon Hemopurifier in the United States.

10 May 2011

Novavax first quarter net loss decreases to $7.5 million

Novavax, Inc. today announced its financial results for the first quarter ended March 31, 2011.

9 May 2011

NBA Cares, SAHM and Tulsa Shock guard partner for teen vaccine awareness campaign

Tulsa Shock guard Andrea Riley and Basketball Hall of Famer Bob Lanier teamed up with NBA Cares and the Society for Adolescent Health and Medicine today to bring Vaccines for Teens to the Tulsa community.

5 May 2011

CEL-SCI receives Polish government approval to commence Multikine Phase III clinical trial in head, neck cancer

CEL-SCI Corporation announced today that it has received approval to begin enrollment of patients in its Phase III clinical trial of Multikine® from the Polish Minister of Health. This approval marks a very important milestone, namely that all nine countries in the study have now given official government approval. Five of about 48 clinical centers for this global trial will be located in Poland.

5 May 2011

NanoViricides' FluCide drug candidate greatly reduces lung viral load in animals

NanoViricides, Inc. reports that post-infection treatment with its optimized FluCide drug candidates achieved 1,000-fold reduction in the levels of infectious virus in the lungs of animals with a lethal level of influenza virus infection.

3 May 2011

Pregnant women with H1N1 more likely to have low birth weight baby

In 2009, the United States was gripped by concern for a new winter threat: the H1N1 strain of influenza. According to research conducted through that winter, pregnant women were right to be concerned.

3 May 2011

MedImmune abstracts on influenza and RSV to be presented at PAS meeting

MedImmune announced today it will present 11 abstracts at the Pediatric Academic Societies Meeting at the Colorado Convention Center in Denver, CO, April 30 - May 3, 2011.

2 May 2011

PURE named winner of CSN 2011 National Child Safety Award

PURE Bioscience, Inc., creator of the patented silver dihydrogen citrate antimicrobial, today announced that Child Safety Network has named PURE the winner of its 2011 National Child Safety Award and has granted PURE Hard Surface disinfectant its Safe Family Seal of Approval.

30 Apr 2011

CEL-SCI receives no objection letter to initiate Phase III clinical trial of Multikine in Canada

CEL-SCI Corporation announced today that the Biologics and Genetic Therapeutics Directorate of Health Canada has issued a final "no objection" letter for CEL-SCI to be able to begin enrollment of patients for a Phase III clinical trial of Multikine in Canada.

30 Apr 2011

Study finds low pediatric flu vaccination acceptance rates in Atlanta

A study of H1N1 and seasonal influenza vaccination in a sample of black and Hispanic children in Atlanta found a low rate of vaccine acceptance among parents and caregivers.

29 Apr 2011

CEL-SCI initiates Multikine Phase III trial in head and neck cancer

CEL-SCI Corporation announced today that it has commenced its global Phase III clinical trial for Multikine, the Company's flagship immunotherapy, at the Meenakshi Mission Hospital and Research Centre in Madurai, Tamil Nadu, India, the first clinical site in India.

28 Apr 2011

PURE Bioscience introduces new Hard Surface disinfectant

PURE Bioscience, Inc., creator of the patented silver dihydrogen citrate antimicrobial, today announced the launch of its proprietary new brand, PURE Hard Surface disinfectant and food contact surface sanitizer at the 2011 California State PTA Annual Convention being held April 28 - May 1 in Long Beach, California.

28 Apr 2011

Aetna first quarter operating earnings is $560.2 million for 2011

Aetna today announced first-quarter 2011 operating earnings of $560.2 million, or $1.43 per share, a per share increase of 46 percent over 2010.

28 Apr 2011

New study sheds light on evolution of 2009 pandemic influenza A(H1N1) virus in Japan

Analysis of mutations of the 2009 pandemic influenza A(H1N1) virus by researchers at the RIKEN Omics Science Center (OSC) has revealed major genetic differences between the virus in its early phase of infection in Japan and in its peak phase. While yielding valuable clues on the genetic origins of drug resistance, the findings also pave the way toward the development of new diagnostic kits for detecting and preventing the spread of global pandemic diseases.

26 Apr 2011

FDA grants Cepheid marketing clearance for Xpert Flu diagnostic test

Cepheid today announced it has received clearance from the U.S. Food & Drug Administration (FDA) to market Xpert® Flu. The diagnostic test, which runs on Cepheid's GeneXpert® System, simultaneously detects and differentiates Influenza A, Influenza B, and the 2009 H1N1 influenza virus in about one hour.

26 Apr 2011

GM-SCF therapy can reduce flu symptoms and prevent death

New research on mice has shown that pulmonary administration of granulocyte macrophage-colony stimulating factor significantly reduces flu symptoms and prevents death after a lethal dose influenza virus.

22 Apr 2011

FDA warns four firms to stop making unproven MRSA prevention claims

The U.S. Food and Drug Administration issued four warning letters to companies that manufacture and market over-the-counter (OTC) drug products, including hand sanitizers, that claim to prevent infection from methicillin-resistant Staphylococcus aureus bacteria (MRSA).

21 Apr 2011

Legionnaire’s bug in Playboy mansion hot tub

Health officials have been able to trace the cause of the outbreak of Legionnaires’ disease after a two-month investigation. They found the bug in the hot tub of the Playboy mansion.

17 Apr 2011

Hospital patients with AUDs are at increased risk of developing HAIs: Study

Hospital patients with alcohol use disorders are at an increased risk of developing healthcare-associated infections, which affect 1.7 million patients annually in the United States. HAIs are infections that patients acquire during their hospitalization and that were not present at the time of admission to the hospital.

16 Apr 2011